Samantha Anderson refused to give up when her triple-negative breast cancer returned. Trusting her oncologist, she enrolled in the clinical trial with Tecentriq (atezolizumab) that led to the approval of the first immunotherapy for this type of breast cancer.
Last modified: October 30, 2019
Subscribe to CONQUER™: the patient voice™ magazine
Receive timely cancer news & updates, patient stories, and more.